Actionable news
All posts from Actionable news
Actionable news in BSX: BOSTON SCIENTIFIC Corp,

Boston Scientific Announces Schedule of Presentations at EuroPCR 2016

MARLBOROUGH, Mass., May 13, 2016 /PRNewswire/ -- Boston Scientific BSX, +2.51% today announced the schedule of key data that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris.

Data from the 1,000-patient EWOLUTION registry, the observational, prospective, non-randomized multicenter study of 'real-world' outcomes with the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device in Europe will be featured as a late-breaking clinical trial on Tuesday, May 17. The 1,000 patient RESPOND study, reporting the safety and efficacy of the Lotus™ Transcatheter Aortic Valve Replacement System used in routine clinical practice will be presented in a hot line session, also on Tuesday, May 17.

Other presentations and abstracts of interest include data supporting products in the Boston Scientific interventional cardiology portfolio. Oral presentations will include the final, five-year outcomes of the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System observed in the EVOLVE trial, as well as two-year clinical outcomes from the EVOLVE II trial, which assesses the SYNERGY Stent in patients with diabetes. Additionally, there will be two oral abstracts which will examine the performance of the Lotus Valve.

"We look forward to facilitating engaging discussions of the data being presented at this year's EuroPCR congress, including the late-breaking clinical data relating to the 'real-world' performance of the WATCHMAN Device, and increasing clinical data collection for patients treated with the SYNERGY Stent and Lotus Valve,"...